Evidence map›Paper›PMID 38188629›Full record

ArticleFrontiers in cellular and infection microbiology2023

The metaproteome of the gut microbiota in pediatric patients affected by COVID-19.

Valeria Marzano, Stefano Levi Mortera, Chiara Marangelo, Antonia Piazzesi, Federica Rapisarda, Stefania Pane, Federica Del Chierico, Pamela Vernocchi, Lorenza Romani, Andrea Campana and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Valeria MarzanoResearch Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Stefano Levi Mortera *Research Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Chiara Marangelo *Research Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Antonia Piazzesi *Research Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Federica Rapisarda *Research Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Stefania PaneUnit of Microbiomics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Federica Del ChiericoResearch Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Pamela VernocchiResearch Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Lorenza RomaniUnit of Infectious Disease, Bambino Gesu' Children's Hospital, IRCCS, Rome, Italy.
Andrea CampanaDepartment of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Paolo PalmaResearch Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Lorenza PutignaniUnit of Microbiomics and Research Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
CACTUS Study Team
Bambino Gesù Children's Hospital · ITIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The gut microbiota (GM) play a significant role in the infectivity and severity of COVID-19 infection. However, the available literature primarily focuses on adult patients and it is known that the microbiota undergoes changes throughout the lifespan, with significant alterations occurring during infancy and subsequently stabilizing during adulthood. Moreover, children have exhibited milder symptoms of COVID-19 disease, which has been associated with the abundance of certain protective bacteria. Here, we examine the metaproteome of pediatric patients to uncover the biological mechanisms that underlie this protective effect of the GM. Methods: We performed nanoliquid chromatography coupled with tandem mass spectrometry on a high resolution analytical platform, resulting in label free quantification of bacterial protein groups (PGs), along with functional annotations via COG and KEGG databases by MetaLab-MAG. Additionally, taxonomic assignment was possible through the use of the lowest common ancestor algorithm provided by Unipept software. Results: A COVID-19 GM functional dissimilarity respect to healthy subjects was identified by univariate analysis. The alteration in COVID-19 GM function is primarily based on bacterial pathways that predominantly involve metabolic processes, such as those related to tryptophan, butanoate, fatty acid, and bile acid biosynthesis, as well as antibiotic resistance and virulence. Discussion: These findings highlight the mechanisms by which the pediatric GM could contribute to protection against the more severe manifestations of the disease in children. Uncovering these mechanisms can, therefore, have important implications in the discovery of novel adjuvant therapies for severe COVID-19.

Indexed as

COVID-19Gastrointestinal MicrobiomeMicrobiotaAdjuvants, ImmunologicAdultAlgorithmsChildHumansAdjuvants, ImmunologicCOVID-19functional patternsgut microbiotamass spectrometrymetaproteomicspediatricsSARS-CoV-2

Identifiers

PMID38188629
PMCPMC10766818
OpenAlexW4390111594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.